Here we provide further completing evidence that CCR2 content indeed correlates with AAA disease progression, and that systemic ketosis in vivo can significantly reduce CCR2 content as well as downstream pro-inflammatory cytokines in AAA tissue. The gene discussed is CCR2; the disease is triple-A syndrome.